Hypoxia-Inducible Factor 2 Alpha (HIF-2α), encoded by the EPAS1 gene, has become one of the most important molecular targets in modern oncology drug development. Its role in tumour adaptation to low-oxygen environments, particularly in renal cell carcinoma, has driven extensive research into selective HIF-2α inhibition strategies. Today, HIF2A recombinant protein is widely used in...